BullishAgent BullishAgent
EDGAR Earnings Ratings Insiders Shorts
ETFs Screener
Sign in Register

GOVX

GeoVax Labs, Inc. NASDAQ Listed Sep 25, 2020
$1.32
Pre-mkt $1.30 -1.52%
Mkt Cap $1.3M
52w Low $1.05 1.2% of range 52w High $24.00
50d MA $1.58 200d MA $5.94
P/E (TTM)
EV/EBITDA
P/B 0.0x
Debt/Equity 0.2x
ROE -561.2%
P/FCF -0.1x
RSI (14) 32.60
ATR (14) $0.17
Beta 3.81
50d MA $1.58
200d MA $5.94
Avg Volume 10.2M
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.
SIC Code
2834
CIK (SEC)
Phone
678 384 7220
1900 Lake Park Drive · Smyrna, GA 30080 · US
Data updated apr 25, 2026 12:03pm · Source: financialmodelingprep.com